The flavonoid Casticin has multiple mechanisms of tumor cytotoxicity action

Cancer Letters

Volumn 242, Issue 2, 2006, Pages 180-190

  Haïdara, Khadidja ^a   Zamir, Lolita ^b   Shi, Qui Wen ^b   Batist, Gerald ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Cdk1; Cell cycle; Cyclins; Flavonoids; p21; p53

Indexed keywords

CASTICIN; CYCLIN A; CYCLIN DEPENDENT KINASE 1; FLAVONOID; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; TUBULIN; UNCLASSIFIED DRUG;

ACHILLEA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CELL KILLING; CELL LINE; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NULL CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CDC2 PROTEIN KINASE; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONOIDS; HUMANS; MODELS, CHEMICAL; MUTATION; NEOPLASMS; PLANT EXTRACTS; TETRAZOLIUM SALTS; THIAZOLES;

ACHILLEA MILLEFOLIUM;

EID: 33749252707     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.11.017     Document Type: Article

References (30)

1. Viallard F.J., Lacombe F., Belloc F., Pellegrin J.F., and Reiffers J. Mécanismes moléculaires contrôlant le cycle cellulaire: aspects fondamentaux et implications en cancérologie. Cancer Radiother. 5 (2001) 109-129
2. Li A., and Blow J.J. The origin of CDK regulation. Nat. Cell Biol. 3 (2001) E182-E184
3. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ. 10 (2003) 431-442
4. Swanton C. Cell cycle targeted therapies. Lancet Oncol. 5 (2004) 27-36
5. Vidal A., and Koff A. Cell-cycle inhibitors: three families united by a common cause. Gene 247 (2000) 1-15
6. Lowe S., Cepero D., and Evan G. Intrinsec tumor supression. Nature 4 (2004) 307-315
7. Longley D.B., and Jonston P.G. Molecular mechanisms of drug resistance. J. Phatol. 205 (2005) 275-292
8. Lee Y.K., Bone N.D., Streg A.K., Jelinek D.F., and Kay N.E. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (ECCG) in B cell chronic lymphocytic leukemia. Blood 104 (2004) 788-794
9. Beliveau R., and Gingras D. Green tea: prevention and treatment of cancer by nutraceuticals. The Lancet 365 (2004) 1021-1022
10. Campbell J.K., Canene-Adams K., Lindshield B.L., Boileau T.W., Clinton S.K., and Erdman Jr. J.W. Tomato phytochemicals and prostate cancer risk. J. Nutr. 134 (2004) 3486S-3492S
11. Shapiro G.I. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin. Cancer Res. 10 (2004) 4270s-4275s
12. Dixon R.A., and Ferreira D. Genistein. Phytochemistry 60 (2002) 205-211
13. You K.M., Son K.H., Chang H.W., Kang S.S., and Kim H.P. Vitexicarpin, a flavonoid from the fruits of Vitex rotundifolia, inhibits mouse lymphocyte proliferation and growth of cell lines in vitro. Planta Med. 64 (1998) 546-550
14. Kobayakawa J., Sato-Nishimori F., Moriyasu M., and Matsukawa Y. G2-M arrest and antimitotic activity mediated by casticin, a flavonoid isolated from Viticis fructus (Vitex rotundifolia linne fil.). Cancer Lett. 208 (2004) 59-64
15. Williams R.G., and Lee J.C. Preparation of tubulin from brain. Methods Enzymol. 85 (1982) 376-385
16. Galmarini C.M., Falette N., Tabone E., Levrat C., Britten R., Voorzanger-Rousselot N., et al. Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity. Br. J. Cancer 85 (2001) 902-908
17. Beutler J.A., Hamel E., Vlietinck A.J., Haemers A., Rajan P., Roitman J.N., et al. Structure-activity requirements for flavone cytotoxicity and binding to tubulin. J. Med. Chem. 41 (1998) 2333-2338
18. Wang L.G., Liu X.M., Kreis W., and Budman D.R. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother. Pharmacol. 44 (1999) 355-361
19. (waf1/cip1) transcription. Oncogene 19 (2000) 961-964
20. Konig A., Schwartz G.K., Mohammad R.M., Katib A.L., and Gabrilove J.L. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-Cell leukaemia lines. Blood 90 (1997) 4307-4312
21. Carlson B., Lahusen T., Singh S., Loaiza-Perez A., Worland P.J., Pestell R., et al. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res. 59 (1999) 4634-4641
22. Taylor W.R., and Stark R.G. Regulation of G2/M transition by p53. Oncogene 20 (2001) 1803-1815
23. Wang H.Y., Cai B., Cui C.B., Zhang D.Y., and Yang B.F. Vitexicarpin, a flavonoid from Vitex trifolia L., induces apoptosis in K562 cells via mitochondria-controlled apoptotic pathway. Yao Xue Xue Bao 40 (2005) 27-31 (article in Chinese)
24. Hollstein M., Rice K., Greenblatt M.S., Soussi T., Fuchs R., Sorlie T., et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22 (1994) 3551-3555
25. Bush J.A., and Li G. Cancer chemoresistance: the relationship between p53 and multidrug transporters. Int. J. Cancer 98 (2002) 323-330
26. Hofseth L.J., Hussein S.P., and Harris C.C. P53: 25 years after its discovery. Trends Pharmacol. Sci. 25 (2004) 177-181
27. Conseil G., Baubichon-Cortay H., Dayan G., Jault J.M., Barron D., and Di Pietro A. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. Proc. Natl Acad. Sci. USA 9 (1998) 9831-9836
28. Comte G., Daskiewicz J.B., Bayet C., Conseil G., Viornery-Vanier A., Dumontet C., et al. Isoprenylation of flavonoids enhances binding affinity toward P-glycoprotein and modulation of cancer cell chemoresistance. J. Med. Chem. 44 (2001) 763-768
29. Scambia G., Ranelletti F.O., Panici P.B., De Vincenzo R., Bonanno G., Ferrandina G., et al. Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother. Pharmacol. 34 (1994) 459-464
30. Limtrakul P., Khantamat O., and Pintha K. Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J. Chemother. 17 (2005) 86-95